Benjamin Besse
Impact in
- Oncology top 0.02%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 377
- Cancer Immunotherapy and Biomarkers 177
- Lung Cancer Research Studies 142
- Colorectal Cancer Treatments and Studies 55
-
- Lung Cancer Treatments and Mutations 327
- Lung Cancer Diagnosis and Treatment 71
- Co-authors
- Jean‐Charles Soria (102 shared papers)David Planchard (132 shared papers)Jordi Remón (82 shared papers)Roberto Ferrara (33 shared papers)Julien Mazières (36 shared papers)Laura Mezquita (84 shared papers)Lizza E.L. Hendriks (42 shared papers)Caroline Caramella (63 shared papers)
- Journals
- Annals of Oncology (157 papers)Journal of Thoracic Oncology (83 papers)European Journal of Cancer (49 papers)Lung Cancer (37 papers)Clinical Cancer Research (27 papers)
- Partner nations
- FranceUnited StatesSpain
In The Last Decade
Benjamin Besse
697 papers receiving 42.3k citations
Benjamin Besse's Hit Papers
Peers
Comparison fields: 5 of 168
- Oncology 21.4k
- Pulmonary and Respiratory Medicine 19.4k
- Cancer Research 6.9k
- Immunology 3.7k
- Molecular Biology 10.6k
Countries citing papers authored by Benjamin Besse
This map shows the geographic impact of Benjamin Besse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Besse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Besse more than expected).
Fields of papers citing papers by Benjamin Besse
This network shows the impact of papers produced by Benjamin Besse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Besse. The network helps show where Benjamin Besse may publish in the future.
Co-authors
The 25 scholars most cited alongside Benjamin Besse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 731 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Hit paper breakdown → | 2013 | 2900 |
| 2 | Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Hit paper breakdown → | 2019 | 1330 |
| 3 | Sotorasib for Lung Cancers with KRAS p.G12C Mutation Hit paper breakdown → | 2021 | 1325 |
| 4 | Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer Hit paper breakdown → | 2012 | 1157 |
| 5 | Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial Hit paper breakdown → | 2017 | 1093 |
| 6 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry Hit paper breakdown → | 2019 | 1055 |
| 7 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 842 |
| 8 | Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Hit paper breakdown → | 2016 | 800 |
| 9 | Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial Hit paper breakdown → | 2016 | 706 |
| 10 | Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer Hit paper breakdown → | 2018 | 706 |
| 11 | Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC Hit paper breakdown → | 2015 | 681 |
| 12 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study Hit paper breakdown → | 2018 | 649 |
| 13 | Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 610 |
| 14 | Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy Hit paper breakdown → | 2018 | 580 |
| 15 | Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial Hit paper breakdown → | 2017 | 565 |
| 16 | Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives Hit paper breakdown → | 2013 | 558 |
| 17 | Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer Hit paper breakdown → | 2022 | 536 |
| 18 | Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial Hit paper breakdown → | 2022 | 531 |
| 19 | CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients Hit paper breakdown → | 2015 | 510 |
| 20 | Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression Hit paper breakdown → | 2021 | 459 |
About Benjamin Besse
Benjamin Besse is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Neurology and Immunology, having authored 731 papers that have together received 43.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (327 papers), Cancer Immunotherapy and Biomarkers (177 papers), Lung Cancer Research Studies (142 papers), Cancer Genomics and Diagnostics (84 papers), Lung Cancer Diagnosis and Treatment (71 papers), Colorectal Cancer Treatments and Studies (55 papers), Myasthenia Gravis and Thymoma (42 papers) and Immunotherapy and Immune Responses (26 papers). The work is most often cited by research in Oncology (21.4k citations), Pulmonary and Respiratory Medicine (19.4k citations), Cancer Research (6.9k citations), Immunology (3.7k citations) and Molecular Biology (10.6k citations). Benjamin Besse has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Jean‐Charles Soria, David Planchard, Jordi Remón, Roberto Ferrara, Julien Mazières, Laura Mezquita, Lizza E.L. Hendriks, Caroline Caramella, Aurélien Marabelle and Nathalie Chaput. Their work appears in journals such as Annals of Oncology, Journal of Thoracic Oncology, European Journal of Cancer, Lung Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.